Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

 

Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050. According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%. The main cause of death from COVID-19 is sepsis, a serious medical condition caused by the body’s reaction to an infection. ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF) proposes to address this problem with a new diagnostic capable of detecting the dysfunctional immune response underlying the most severe form of sepsis. Other companies like ImmunityBio, Inc. (NASDAQ:IBRX), Dynavax Technologies Corporation (NASDAQ:DVAX), Allogene Therapeutics (NASDAQ:ALLO) and Ensysce Biosciences (NASDAQ:ENSC) are looking to combat COVID-19 and cancer.

ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF), through its subsidiary ASEP Medical Inc., focuses on the development of an early diagnostic tool for sepsis and peptide therapy treatments for multiple applications. The company, which entered the public markets in December 2021, just commenced trading on the OTCQB Venture market under the symbol SEPSF.

In February, ASEP Medical Holdings announced that it has finalized an exclusive licensing arrangement with UBC for a patented and potentially groundbreaking AI-driven sepsis diagnosis technology.  The technology, which was developed under the direction of leading UBC microbiologist and Asep Medical’s Founding Director and COO, Dr. Robert Hancock, enables early and accurate diagnosis of the deadly disease sepsis. Sepsis, which occurred in 48.9 million people worldwide and caused 11 million deaths globally in 2017, has become increasingly concerning during the global pandemic.

ASEP Medical is addressing this disease head-on with its novel diagnostic test SepsetER, which senses the dysfunctional immune response underlying sepsis when the patients first enter the emergency room. The test is a blood-based gene expression assay that is straightforward to implement, and offers results within 1-2 hours in the emergency room or intensive care unit (ICU). Current diagnostic tools deliver results within 24-36 hours, often delaying the initiation of treatment. SepsetER enables physicians to quickly predict the severity of sepsis and define better, more immediate treatment options for the patient. 

On March 21, ASEP Medical revealed compelling results from a study completed by RTI Health Solutions, a leading US-based research consultancy specializing in health economics and outcomes research.

According to RTI Health’s research and findings, “Overall, early and appropriate antibiotic treatment is associated with an absolute decrease of 7% in mortality and a reduction of length of stay in the hospital of 5.85 days. This results in a reduction in costs of $14,555 in patients with sepsis without organ dysfunction, $17,134 in patients with sepsis with organ dysfunction, and $19,300 in patients with septic shock.” Given the prevalence of sepsis, the report reveals this could result in an overall savings of up to $22 billion annually in the US alone (calculated by multiplying the estimated savings per hospital by the number of relevant hospitals in the US).

For more information about ASEP Medical Holding Inc. (CSE:ASEP) (OTCQB:SEPSF), click here.

Biotech Companies Are Working on Preventing Covid-19 and Treating Cancer

ImmunityBio, Inc. (NASDAQ:IBRX), a clinical-stage immunotherapy company, and Amyris Inc, a leading synthetic biotechnology company, announced on January 3 the completion of a previously announced joint venture agreement to accelerate the commercialization of a next-generation RNA COVID-19 vaccine. Upon completion of successful human trials and regulatory approval, the goal of the joint venture is to begin delivering the second-generation vaccine in 2022. ImmunityBio and Amyris aim to provide immunity for COVID-19 and access to underserved areas of the world where current vaccine technology is challenged due to cost and supply chain limitations.

Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on the development and commercialization of vaccines, announced on December 28 that Biological E reported that CORBEVAX ™, its COVID-19 vaccine which contains the adjuvant Dynavax‘s CpG 1018® adjuvant, has received approval for emergency use from Drugs Controller General of India (DCGI). Dynavax and Biological E previously announced the execution of a Commercial Supply Agreement (CSA) for Dynavax to supply its adjuvant CpG 1018 for use in Biological E’s CORBEVAX.

On December 15, Allogene Therapeutics (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, announced that it has entered into a lease agreement to expand its headquarters in South San Francisco, California. The lease is scheduled to begin April 1, 2022, and the additional 47,566 square feet of office and laboratory space will supResistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and put in place, 10 million people could die from antibiotic resistance-related diseases by 2050. According to SPER Market Research, the global antimicrobial resistance (AMR) market was valued at US$10.2 billion in 2021 and estimated at US$16.4 billion by 2030 with a CAGR of 5.74%. The main cause of death from COVID-19 is sepsis, a serious medical condition caused by the body’s reaction to an infection. ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF) proposes to address this problem with a new diagnostic capable of detecting the dysfunctional immune response underlying the most severe form of sepsis. Other companies like ImmunityBio, Inc. (NASDAQ:IBRX), Dynavax Technologies Corporation (NASDAQ:DVAX), Allogene Therapeutics (NASDAQ:ALLO) and Ensysce Biosciences (NASDAQ:ENSC) are looking to combat COVID-19 and cancer.

ASEP Medical Holdings Inc. (CSE:ASEP) (OTCQB:SEPSF), through its subsidiary ASEP Medical Inc., focuses on the development of an early diagnostic tool for sepsis and peptide therapy treatments for multiple applications. The company, which entered the public markets in December 2021, just commenced trading on the OTCQB Venture market under the symbol SEPSF.

In February, ASEP Medical Holdings announced that it has finalized an exclusive licensing arrangement with UBC for a patented and potentially groundbreaking AI-driven sepsis diagnosis technology.  The technology, which was developed under the direction of leading UBC microbiologist and Asep Medical’s Founding Director and COO, Dr. Robert Hancock, enables early and accurate diagnosis of the deadly disease sepsis. Sepsis, which occurred in 48.9 million people worldwide and caused 11 million deaths globally in 2017, has become increasingly concerning during the global pandemic.

ASEP Medical is addressing this disease head-on with its novel diagnostic test SepsetER, which senses the dysfunctional immune response underlying sepsis when the patients first enter the emergency room. The test is a blood-based gene expression assay that is straightforward to implement, and offers results within 1-2 hours in the emergency room or intensive care unit (ICU). Current diagnostic tools deliver results within 24-36 hours, often delaying the initiation of treatment. SepsetER enables physicians to quickly predict the severity of sepsis and define better, more immediate treatment options for the patient. 

On March 21, ASEP Medical revealed compelling results from a study completed by RTI Health Solutions, a leading US-based research consultancy specializing in health economics and outcomes research. 

port the growth of its research platform and related clinical development activities. With this lease, the company will occupy more than 100,000 square feet at its headquarters in South San Francisco. Additionally, Allogene built Cell Forge 1, a state-of-the-art cell therapy manufacturing facility in Newark, California.

Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage biotechnology company with new technology platforms that can bring new hope to people with severe pain, announced on January 5 that it will participate in the H.C. Wainwright BIOCONNECT Conference which will be held virtually January 10-13, 2022. Ensysce uses nafamostat mesylate (Nafamostat), a synthetic protease inhibitor, in its efforts to stop opioid abuse and overdoses specifically in its MPAR™ class of agents. Research shows that Nafamostat may be effective in preventing or reducing the lethal outcome of COVID-19  infection.

As sepsis and antibiotic-resistant infections continue to take a toll on the healthcare system, ASEP Medical Holding Inc. offers excellent investment potential and robust growth.

[BONUS-POPUP id=”1″]

Please See Disclaimer

Featured Image: DepositPhotos @ diego_cervo


Disclosure:

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, ASEP Medical Holdings Inc. Market Jar Media Inc. has or expects to receive from Pure Extracts Technologies Corp’s Digital Marketing Agency of Record (Native Ads Inc.) one hundred ninety-one thousand eight hundred dollars CAD for 23 days (17 business days).

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on MicroSmallCap.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on MicroSmallCap.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding ASEP Medical Holdings Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to ASEP Medical Holdings Inc.’s industry; (b) market opportunity; (c) ASEP Medical Holdings Inc.’s business plans and strategies; (d) services that ASEP Medical Holdings Inc. intends to offer; (e) ASEP Medical Holdings Inc.’s milestone projections and targets; (f) ASEP Medical Holdings Inc.’s expectations regarding receipt of approval for regulatory applications; (g) ASEP Medical Holdings Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) ASEP Medical Holdings Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute ASEP Medical Holdings Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) ASEP Medical Holdings Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) ASEP Medical Holdings Inc.’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) ASEP Medical Holdings Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of ASEP Medical Holdings Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) ASEP Medical Holdings Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact ASEP Medical Holdings Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing ASEP Medical Holdings Inc.’s business operations (e) ASEP Medical Holdings Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, ASEP Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does ASEP Medical Holdings Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither ASEP Medical Holdings Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of ASEP Medical Holdings Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of ASEP Medical Holdings Inc. or such entities and are not necessarily indicative of future performance of ASEP Medical Holdings Inc. or such entities.